Neoadjuvant FEC 100 for Operable Breast Cancer: Eight-Year Experience at Centre Jean Perrin
2004; Elsevier BV; Volume: 5; Issue: 4 Linguagem: Inglês
10.3816/cbc.2004.n.035
ISSN1938-0666
AutoresMarie‐Ange Mouret‐Reynier, Catherine Abrial, Jean-Pierre Ferrière, S. Amat, Hervé Curé, Fabrice Kwiatkowski, V. Feillel, Guillaume Lebouëdec, Frédérique Penault‐Llorca, P. Chollet,
Tópico(s)Breast Lesions and Carcinomas
ResumoThis study investigated the efficacy and tolerability of FEC 100 (epirubicin 100 mg/m2 with 5-fluorouracil 500 mg/m2 and cyclophosphamide 500 mg/m2) every 21 days as neoadjuvant chemotherapy in women with stage I-III primary operable breast cancer. Forty patients were treated with 6 cycles of FEC 100, followed by surgery and radiation therapy. In addition, most patients also received an adjuvant treatment for residual disease (11 chemotherapies and 31 tamoxifen). After 6 cycles of FEC 100, the overall clinical response rate of 75% (CI 95%, 61.6-88.4) was achieved, 22.5% of which were complete responses. Breast conservation was achieved in 70% of patients. A pathologic complete response was confirmed in 6 patients (15%; CI 95%, 3.9—26.1) using Chevallier's classification and in 10 patients (25%; CI 95%, 11.6–38.4) using Sataloff's classification. After a median follow-up of 29.5 months, 3 metastatic relapses were observed. The principal toxicity of FEC 100 was myelosuppression; 51.3% of patients developed grade 3/4 neutropenia. Neoadjuvant FEC 100 was both effective and well tolerated in patients with early-stage operable breast cancer.
Referência(s)